The safety and tolerability of the combination of ipilimumab and axitinib will be tested in advanced melanoma patients who are intolerable/refractory to anti-PD-1/PD-L1 therapy and have not previously received treatment with ipilimumab.
The goal of this clinical research study is to find out if taking axitinib with ipilimumab is effective in treating advanced melanoma.